A pilot, randomized controlled trial of Dual Daily HIV and sexually transmitted infection pre-exposure prophylaxis using tenofovir disoproxil fumarate/emtricitabine and doxycycline in gay, bisexual and other men who have sex with men and transgender women: The DuDHS Study.

IF 7.3 1区 医学 Q1 IMMUNOLOGY Clinical Infectious Diseases Pub Date : 2025-01-30 DOI:10.1093/cid/ciaf043
Troy Grennan,Saira Mohammed,Joshua Edward,Tessa Tattersall,Amit K Gupta,Joyce Seto,Michelle Dennehy,Marc G Romney,Wendy Zhang,Jenny Li,Jason Trigg,Viviane D Lima,Stephen Juwono,Jason Wong,Guijun Zhang,Julio S G Montaner,Mark W Hull
{"title":"A pilot, randomized controlled trial of Dual Daily HIV and sexually transmitted infection pre-exposure prophylaxis using tenofovir disoproxil fumarate/emtricitabine and doxycycline in gay, bisexual and other men who have sex with men and transgender women: The DuDHS Study.","authors":"Troy Grennan,Saira Mohammed,Joshua Edward,Tessa Tattersall,Amit K Gupta,Joyce Seto,Michelle Dennehy,Marc G Romney,Wendy Zhang,Jenny Li,Jason Trigg,Viviane D Lima,Stephen Juwono,Jason Wong,Guijun Zhang,Julio S G Montaner,Mark W Hull","doi":"10.1093/cid/ciaf043","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nMen who have sex with men (MSM) and transgender women experience high sexually transmitted infection (STI) rates. This study evaluated the feasibility of doxycycline pre-exposure prophylaxis (doxyPrEP) for STI prevention in these key populations.\r\n\r\nMETHODS\r\nSexually-active MSM and transgender women without HIV with prior syphilis were recruited. Participants initiated HIV PrEP with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) daily for 48 weeks, and were randomized 1:1 to daily doxyPrEP for 48 weeks (immediate arm), or doxyPrEP initiated at 24 weeks (deferred arm). Primary outcomes included adherence, measured using questionnaires, along with tolerability; STI incidence (chlamydia, gonorrhea, syphilis) was a secondary outcome. Nasal carriage of S. aureus was assessed serially for doxycycline resistance.\r\n\r\nRESULTS\r\nFifty-two participants were enrolled into the immediate (n=26) and deferred (n=26) arms. At 48 weeks, self-reported adherence (≥95%) was 75.0% vs. 66.7% (p=0.538) for TDF/FTC, and 70.8% vs. 61.9% (p=0.526) for doxycycline in the immediate vs. deferred arms, respectively. No doxyPrEP-related serious adverse events occurred. Incidence of any STI at 24 weeks was reduced in the immediate vs. deferred arms, and over 48 weeks, being on doxycycline (vs. being off; i.e. first 24 weeks of deferred arm) was associated with STI reduction (adjusted odds ratio [aOR] 0.36; 95 % confidence interval [CI] 0.15-0.89). Emergent doxycycline-resistant S. aureus was identified in six individuals, with five in the immediate arm (p=0.077).\r\n\r\nCONCLUSIONS\r\nDual HIV/doxyPrEP is feasible and associated with a significant reduction in incident STI. Further evaluation of dosing strategies, efficacy and impact on antimicrobial resistance is warranted.","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":"36 1","pages":""},"PeriodicalIF":7.3000,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cid/ciaf043","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND Men who have sex with men (MSM) and transgender women experience high sexually transmitted infection (STI) rates. This study evaluated the feasibility of doxycycline pre-exposure prophylaxis (doxyPrEP) for STI prevention in these key populations. METHODS Sexually-active MSM and transgender women without HIV with prior syphilis were recruited. Participants initiated HIV PrEP with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) daily for 48 weeks, and were randomized 1:1 to daily doxyPrEP for 48 weeks (immediate arm), or doxyPrEP initiated at 24 weeks (deferred arm). Primary outcomes included adherence, measured using questionnaires, along with tolerability; STI incidence (chlamydia, gonorrhea, syphilis) was a secondary outcome. Nasal carriage of S. aureus was assessed serially for doxycycline resistance. RESULTS Fifty-two participants were enrolled into the immediate (n=26) and deferred (n=26) arms. At 48 weeks, self-reported adherence (≥95%) was 75.0% vs. 66.7% (p=0.538) for TDF/FTC, and 70.8% vs. 61.9% (p=0.526) for doxycycline in the immediate vs. deferred arms, respectively. No doxyPrEP-related serious adverse events occurred. Incidence of any STI at 24 weeks was reduced in the immediate vs. deferred arms, and over 48 weeks, being on doxycycline (vs. being off; i.e. first 24 weeks of deferred arm) was associated with STI reduction (adjusted odds ratio [aOR] 0.36; 95 % confidence interval [CI] 0.15-0.89). Emergent doxycycline-resistant S. aureus was identified in six individuals, with five in the immediate arm (p=0.077). CONCLUSIONS Dual HIV/doxyPrEP is feasible and associated with a significant reduction in incident STI. Further evaluation of dosing strategies, efficacy and impact on antimicrobial resistance is warranted.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一项针对男同性恋、双性恋和其他男男性行为者以及变性女性使用富马酸替诺福韦二氧丙酯/恩曲他滨和多西环素进行每日双重HIV和性传播感染暴露前预防的随机对照试验:DuDHS研究
男男性行为者(MSM)和变性女性的性传播感染(STI)率很高。本研究评估了多西环素暴露前预防(doxyPrEP)在这些关键人群中预防STI的可行性。方法招募性活跃的男男性行为者和变性女性,无HIV,既往梅毒。参与者每天使用富马酸替诺福韦二氧吡酯/恩曲他滨(TDF/FTC)开始HIV PrEP,持续48周,并按1:1随机分配到每天使用doxyPrEP 48周(立即组),或在24周(延迟组)开始使用doxyPrEP。主要结局包括使用问卷测量的依从性和耐受性;性传播感染发生率(衣原体、淋病、梅毒)是次要结果。连续评估金黄色葡萄球菌鼻腔携带的多西环素耐药性。结果52名受试者被纳入即时组(n=26)和延迟组(n=26)。48周时,TDF/FTC组自我报告的依从性(≥95%)分别为75.0%和66.7% (p=0.538),强力霉素组即时组和延迟组分别为70.8%和61.9% (p=0.526)。未发生与doxyprep相关的严重不良事件。即刻治疗组与延期治疗组相比,24周时任何STI的发生率都有所降低;超过48周时,服用强力霉素组(与停用强力霉素组相比;即延迟治疗前24周)与STI减少相关(调整优势比[aOR] 0.36;95%置信区间[CI] 0.15-0.89)。在6例患者中发现了紧急耐多西环素金黄色葡萄球菌,其中5例在直接臂中(p=0.077)。结论HIV/doxyPrEP双重治疗是可行的,可显著降低性传播感染发生率。有必要进一步评估给药策略、疗效和对抗菌素耐药性的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Infectious Diseases
Clinical Infectious Diseases 医学-传染病学
CiteScore
25.00
自引率
2.50%
发文量
900
审稿时长
3 months
期刊介绍: Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.
期刊最新文献
Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study. Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults Living With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From Two Open-Label, Phase 1 Studies. When are uncontrolled trials in TB scientifically and ethically justified: Borrowing wisdom from early AIDS clinical trials. A Turning Point for Hepatitis C Care: Point-of-Care HCV RNA Authorization as a Critical First Step Towards Integrated Test-and-Treat Models in the United States. Performance Evaluation of the Xpert® HCV test on Fingerstick Blood in a Prospective Observational Clinical Study at CLIA-Waived Sites in the United States.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1